| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Lyra Therapeutics Inc. | LYR-220 - (BEACON) | Chronic rhinosinusitis | Phase 2 | Clinical Pause | Intranasal | Respiratory |
| Lyra Therapeutics Inc. | LYR-210 - (LANTERN) | Chronic rhinosinusitis / Chronic Sinusitis | Phase 2 | Trial Discontinued | Intranasal | Respiratory |
| MacroGenics Inc. | ZYNYZ (retifanlimab-dlwr) - (POD1UM-304) | Non-small cell lung cancer (NSCLC) | PDUFA | Data Released | Intravenous | Oncology |
| MacroGenics Inc. | MARGENZA (margetuximab) and MGA012 (MAHOGANY) | Gastric cancer | Phase 2/3 | Intravenous | Oncology | |
| MacroGenics Inc. | Retifanlimab | Anal cancer | Phase 2 | Trial Completed | Intravenous | Oncology |
| MacroGenics Inc. | MGC018 - (TAMARACK) | Metastatic castration-resistant prostate cancer (mCRPC) | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| MacroGenics Inc. | Enoblituzumab | Localized Prostate Cancer | Phase 2 | Ongoing | Intravenous | Oncology |
| MacroGenics Inc. | Enoblituzumab, retifanlimab and tebotelimab | Squamous cell carcinoma of the head and neck (SCCHN) | Phase 2 | Intravenous | Oncology |